問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊永立

Recruiting

List

26Cases

2020-04-01 - 2026-09-30

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-04-01 - 2027-01-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-12-01 - 2025-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-10-17 - 2028-12-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2022-02-28 - 2025-08-18

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2021-11-01 - 2029-08-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-11-01 - 2029-03-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2018-03-18 - 2024-10-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2020-01-01 - 2026-12-31

Phase I/II

A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations

  • Condition/Disease

    Advanced or metastatic malignancies

  • Test Drug

    Repotrectinib

Participate Sites
2Sites

Recruiting2Sites

2020-08-01 - 2023-11-23

Phase I/II

A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

  • Condition/Disease

    Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

  • Test Drug

    ENTRECTINIB (RXDX-101)

Participate Sites
2Sites

Recruiting2Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB